Business Wire

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas

Parse’s GigaLab to provide industry leading, large-scale, single cell services to support Tahoe’s development of foundational biological datasets SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading ...
Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational ...
Morningstar

FDA approves Omisirge(R) as First Approved Cell Therapy to Treat Severe Aplastic Anemia

DUBLIN, IE AND LONDON, UK / ACCESS Newswire / December 5, 2025 / Ayrmid Ltd. ("Ayrmid" or the "Company"), the parent company of Gamida Cell Inc., a leader in cell therapy innovation announces that it ...
Morningstar

Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a broad patient population2 Olanzapine LAI is designed to ...